ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopia, a Common and Progressive Eye Condition
July 30, 2021Allergan today announced new data, including the full results from the Phase 3 GEMINI 1 clinical study, evaluating the efficacy, safety and tolerability of investigational AGN-190584 ophthalmic solution for the treatment of presbyopia. -
Allergan Announces Positive Phase 3 Topline Results for Presbyopia Trial
November 05, 2020Allergan, an AbbVie company, announced the Phase 3 GEMINI 1 and 2 clinical trials evaluating the efficacy, safety and tolerability of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of symptoms associated with ...
Pharma Sources Insight January 2025
